GlassScriptPhysician profile
Vitasta Bamezai
NPI 1396704318
$3,521.06
in general payments reported to CMS, 2019-2025
39 companies · $543 in 2025
The $543 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $885 · 2020: $253 · 2022: $500 · 2023: $782 · 2024: $559 · 2025: $543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,884.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,883.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $583.37 | 2022-2025 | Vraylar, Ubrelvy, Synthroid |
| Pfizer INC. | $437.00 | 2019-2025 | |
| Novo Nordisk INC | $385.86 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $314.09 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $206.86 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $185.90 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Abbott Laboratories | $153.93 | 2019-2025 | Eterna, Freestyle Libre 2, Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $123.20 | 2023-2025 | |
| Astellas Pharma US INC | $118.39 | 2019-2023 | Myrbetriq |
| E.R. Squibb & Sons, L.L.C. | $97.12 | 2019-2025 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $87.59 | 2022-2024 | |
| Shield Therapeutics INC | $79.98 | 2024 | |
| Janssen Pharmaceuticals, INC | $69.70 | 2019 | |
| Merck Sharp & Dohme LLC | $55.02 | 2019 | |
| Exact Sciences Corporation | $47.47 | 2023-2025 | Cologuard Collection Kit |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vitasta Bamezai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.